Invitrogen to Use Gryphon Technology to Expand Proteomic Property | GenomeWeb

NEW YORK, Oct. 19 - Invitrogen has been granted a non-exclusive sub-license from Gryphon Sciences to use its Native Chemical Ligation patent, which allow researchers to synthesize proteins using chemical, rather than biological means, Gryphon said on Friday.

The patent, numbered 6,184,344 and entitled "Synthesis of Proteins by Native Chemical Ligation," covers processes for making proteins that retain the biologic activity of the native molecule and can have specific functionality built into them, according to Gryphon. 

Financials terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.